NEW YORK, June 5 /PRNewswire-FirstCall/ -- American Oriental Bioengineering (NYSE: AOB) announced today that it has withdrawn its convertible preferred stock offering. The decision to cancel its convertible preferred stock offering at this time was principally due to prevailing market conditions resulting in terms that were not acceptable to the Company.
Note Regarding Forward-Looking Statements
Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended December 31, 2007 and the Form 10-Q for the three months ended March 31, 2008, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.
About American Oriental Bioengineering
American Oriental Bioengineering, Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products in China. For more information, visit http://www.bioaobo.com .
SOURCE American Oriental Bioengineering, Inc.